![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 04, 2023 4:02:49 PM
https://investor.regeneron.com/static-files/dbe7aad3-8aff-483f-9366-fa1678d7b738
Multiple potential FDA submissions: 2023-2025+
DUPIXENT*
Type 2 COPD
LIBTAYO
Adjuvant CSCC
Fianlimab + LIBTAYO
Advanced Melanoma
PRALUENT
Pediatric HeFH (mid)
DUPIXENT*
CPUO
Pozelimab ± cemdisiran+
C5-mediated diseases
Odronextamab
B-Cell NHL (2H)
DUPIXENT*
Bullous Pemphigoid
Garetosmab
FOP
Linvoseltamab
R/R Multiple Myeloma (2H)
Aflibercept 8 mg
RVO
Itepekimab*
COPD
M
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM